See more : Vivara Participações S.A. (VIVA3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Zenas BioPharma, Inc. (ZBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zenas BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Imerys S.A. (IMYSY) Income Statement Analysis – Financial Results
- PORTFOLIOMANAGER ØU INVEST BALANCE KL N (PMIOUIB.CO) Income Statement Analysis – Financial Results
- Arden Partners plc (ARDN.L) Income Statement Analysis – Financial Results
- J Frontier Co.,Ltd. (2934.T) Income Statement Analysis – Financial Results
- Krakchemia S.A. (KCH.WA) Income Statement Analysis – Financial Results
Zenas BioPharma, Inc. (ZBIO)
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows
Zenas BioPharma Seeks IPO For Inflammatory Treatment Trials
U.S. IPO Weekly Recap: WeRide Delays Its IPO As Pipeline Gets A Boost
Source: https://incomestatements.info
Category: Stock Reports
What is Zenas BioPharma’s current cash balance?
The company reported a net loss of $38.6 million. Cash balance stands at $386.8 million, expected to fund operations into Q4 2026.
When are the topline results for the INDIGO trial expected?
With the completion of targeted enrollment for the largest clinical trial ever conducted in this patient population, the Company expects to report topline results for INDIGO by the end of 2025.